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Alterations in basal metabolic substrate preference were proposed as early 
derangements in the development of skeletal muscle insulin resistance. Here, we 
report that alterations in muscle substrate oxidation are not associated with muscle 
insulin resistance in rats or humans. In this study we used a novel stable isotope 
tracer ([U-13C]glucose) liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method to measure the ratio of mitochondrial glucose oxidation by 
pyruvate dehydrogenase flux (VPDH) relative to rates of citrate synthase flux (VCS) 
in skeletal muscle. We found that high fat diet (HFD) fed insulin resistant rats did 
not have altered substrate oxidation in soleus muscle in the fasting state. 
Hyperinsulinemic-euglycemic clamps increased relative glucose oxidation in both 
normal and insulin resistant rats, although this increase was blunted in HFD fed 
insulin resistant rats, due to an impairment in insulin-stimulated muscle glucose 
transport. Additionally, we found that an acute infusion of lipid during a 
hyperinsulinemic-euglycemic clamp in normal rats significantly reduced 
mitochondrial VPDH/VCS flux in soleus muscle without any effects on insulin-
stimulated peripheral glucose metabolism or muscle glucose transport. Using the 
same stable isotope/LC-MS/MS approach we then examined VPDH/VCS flux in 
insulin sensitive and insulin resistant humans and found similar relative rates of 
VPDH/VCS following an overnight fast and similar increases in VPDH/VCS fluxes during 
a hyperinsulinemic-euglycemic clamp. Taken together these results show that 
basal mitochondrial substrate preference in muscle is not altered in insulin 
resistant rats or insulin resistant humans and that acute modulation of substrate 
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oxidation in normal rats does not affect muscle insulin sensitivity refuting the 
metabolic inflexibility hypothesis which stipulates that alterations in substrate 
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I. Insulin Resistance and Type 2 Diabetes 
Type 2 Diabetes (T2D) is emerging as a global epidemic, with the prevalence of 
the disease increasing at a rate far exceeding previous predictions (1,2), with close 
to 50 million people expected to live with T2D by the year 2030 (3). The age of 
onset of T2D has inched earlier, and the prevalence of the disease has increased 
among children and adolescents in recent years (4,5). These trends portend a 
distressing future: the United States alone spent more than $170 billion in 2007 for 
treatment of diabetes and its associated complications (6), and the disease is 
expected to exact a heavy cost from economies around the world. 
Despite the widespread and increasing prevalence of T2D and the 
significant attention devoted to its study, the precise molecular mechanisms 
leading to the development of T2D remain relatively poorly characterized. T2D can 
be defined as the progressive development of insulin resistance accompanied by 
the failure of insulin secretion that culminates in the clinical manifestation of 
inappropriate fasting hyperglycemia. The exact sequence of these components – 
as well as the relative importance of each – continues to be debated, but growing 
evidence has pointed to the centrality of insulin resistance as the key event in the 
pathogenesis of T2D (7–9). Impaired glucose disposal in response to insulin is 
seen as one of the earliest defects in susceptible individuals (8–10). In fact, islet 
cells increase insulin secretion in the early stages of diabetes during a period of 
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compensated, subclinical insulin resistance (i.e. without overt hyperglycemia); 
when β-cells are no longer able to compensate – either from the severity of insulin 
resistance or due to a number of genetic factors that may predispose it to failure – 
the patient manifests clinically with diabetes (11,12). Thus, understanding insulin 
resistance and the precise molecular steps leading to its development is key to 
understanding T2D and to developing potential therapies. 
As master regulator of metabolism, insulin accomplishes a variety to key 
tasks in disparate organ systems, which include 1) the suppression of lipolysis (or 
the breakdown and release of fatty acids) in adipose tissue, 2) the shift from 
gluconeogenesis to glycogen storage and lipogenesis in the liver, and 3) the 
stimulation of glucose uptake and glycogen storage in skeletal muscle (7). These 
varied effects ultimately converge to aid the body in the fasting to fed transition; 
from the reliance on endogenous glucose production (performed by the liver and 
crucial for obligate glucose utilizers like the brain) and fat/ketone oxidation (which 
occurs in peripheral tissues like skeletal muscle) during times of nutrient 
deprivation, to the storage and usage of exogenous glucose in times of nutrient 
abundance (7,13). Insulin resistance, put simply, is the inability of insulin to 
produce these effects in its target cells. 
Skeletal muscle is a particularly important site of insulin action, as well as a 
crucial player in the development of insulin resistance and T2D. For one, skeletal 
muscle has a disproportionate influence on whole-body glucose homeostasis, as 
it accounts for a major fraction of insulin-stimulated extrahepatic glucose uptake 
(10). Furthermore, abnormalities in skeletal muscle – such as disordered nutrient 
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storage, intramyocellular ectopic lipid accumulation, and associated impairments 
in insulin-stimulated glucose uptake – have been observed in predisposed 
individuals decades before the onset of frank T2D (8,14–16), suggesting that 
derangements in skeletal muscle are some of the earliest to occur in the 
pathogenesis of T2D, perhaps even earlier than dysfunctions in hepatic insulin 
response. Third, exercise has been shown to stimulate glucose uptake in insulin 
resistant muscle in an insulin-independent manner (17–19), emphasizing skeletal 
muscle’s current and potential role (through both behavioral and pharmaceutical 
approaches) in the treatment of T2D. 
Despite intense study, the precise location of muscle insulin resistance – 
that is, the molecular defect that prevents insulin from eliciting its normal 
physiologic response in muscle – remains an unsolved mystery. Many of insulin’s 
physiologic intracellular actions have been characterized: insulin’s binding to its 
receptor sets off a cascade of events in the myocyte including heterodimerization 
and autophosphorylation of the insulin receptor (a member of the tyrosine kinase 
receptor family) and recruitment of key downstream mediators such as insulin 
receptor substrate-1 (IRS-1), phosphoinositide-3 kinase (PI3K), and AKT. These 
events ultimately serve to increase the translocation of the glucose transporter 
GLUT4 to the membrane, increase glucose influx into the cell, increase the rate of 
glycolysis, and increase glycogen synthesis (20–24). Many of these steps (as well 
as other steps in insulin-independent pathways) have been implicated in the 





II. Muscle Substrate Oxidation and the Metabolic Inflexibility Hypothesis 
In this setting, alterations in mitochondrial substrate preference and oxidation have 
been hypothesized as essential derangements in skeletal muscle insulin 
resistance. Mitochondria are the site of oxidative disposal of acetyl-CoA, the end 
product of both glycolysis and β-oxidation of fatty acids. In a seminal study 
published more than 50 years ago, Randle et al. proposed that skeletal muscle 
glucose and fat oxidation existed in competition within the myocyte and that 
disordered oxidation of fat could in turn effect intracellular handling of glucose. 
Based on a series of in vitro experiments in the rat heart, Randle observed that 
increasing fat oxidation in the myocyte could directly inhibit glycolysis by increasing 
the levels of key metabolites that could allosterically inhibit enzymes in the 
glycolytic pathway, ultimately leading to the inhibition of glucose uptake in to the 
cell. From these observations, Randle proposed that this intracellular glucose-fatty 
acid cycle (nicknamed the “Randle cycle”) explains how 1) in normal individuals, 
the physiologic increase in the availability of fatty acids in the fasting state leads to 
an increase in fat oxidation and concomitant decrease in glucose oxidation in 
myocytes and 2) in insulin resistant individuals, pathologically elevated fat 
oxidation could inhibit glucose oxidation and, in turn, glucose uptake in myocytes 
(25) (Graphic 1). The hypothesis notably did not require the implication of defects 
in intracellular insulin signaling; increased fat oxidation (either directly through 
altered mitochondrial preference, or indirectly through increased delivery of fatty 
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acids to the myocyte) could reduce muscle glucose uptake regardless of changes 
in insulin signaling. While Randle’s observations and predictions failed to be 
confirmed in subsequent in vivo experiments, the ‘Randle cycle’ represented in its 
time a novel and attractive explanation that connected mitochondrial substrate 
handling and whole-body glucose homeostasis. 
More recently and in a similar vein, the concept of ‘metabolic inflexibility’ 
has been proposed to cause muscle insulin resistance. The metabolic inflexibility 
hypothesis, proposed by David Kelley, also placed disordered mitochondrial 
substrate handling as the locus of insulin resistance, rather than defects in the 
insulin signaling cascade. In his in vivo experiments in humans, Kelley used leg-
specific indirect calorimetry techniques1 to measure muscle substrate oxidation 
and compare them between normal and insulin resistant subjects. Kelley found 
that that while the muscles of normal individuals relied predominantly on fat 
oxidation in the fasting state and on glucose oxidation in the insulin-stimulated 
state, insulin resistant individuals 1) had paradoxically increased preference for 
glucose oxidation in the fasting state and 2) could not modulate their muscle 
substrate preference in response to insulin (26,27). Stated another way, insulin 
resistant muscle seemed to be ‘locked in’ to a particular ratio of glucose to fat 
oxidation and could not adjust its oxidative fuel based on physiological 
                                            
1 Indirect calorimetry refers to the measurement of the arteriovenous differential in oxygen and 
carbon dioxide content (in this case, across the leg) to approximate relative substrate oxidation in 
myocytes. The technique centers on knowing the predicted stoichiometries of oxygen consumption 
and carbon dioxide production for the oxidation of specific substrates (glucose, fat, ketone, amino 
acid). In the case of humans in normal physiologic conditions, glucose and fatty acids were 
assumed to be the major oxidative substrates in muscle. 
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circumstance, fasting or fed.  Kelley went on to conclude from these observations 
that insulin resistance was a manifestation of underlying cellular ‘metabolic 
inflexibility,’ or the inability to alter substrate oxidation in varying physiologic states: 
metabolically inflexible myocytes operated at a saturated rate of glucose oxidation 
that created an intracellular backlog unfavorable to further glucose uptake, even in 
the setting of insulin (28). He further hypothesized that defects in the mitochondrial 
enzymatic machinery that regulates both basal substrate metabolism and 
transitions between glucose and fat oxidation were mechanistically responsible for 
the onset of diabetes.  
The concept of metabolic inflexibility has gained considerable traction in the 
field of metabolism, and recent studies have proposed aberrations in pyruvate 
dehydrogenase (PDH) (29), pyruvate dehydrogenase kinase (PDK) isoforms (30), 
carnitine-palmitoyl transferase-1 (31), and carnitine acetyltransferase (CrAT) (32) 
as possible mediators of altered basal substrate handling in insulin resistant 
muscle and, therefore, as potential therapeutic targets in T2D. 
 
(Continued on page 13)  
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Graphic 1. A schematic of the proposed Randle cycle, which shows that increased fat oxidation results in an 
increase in acetyl-CoA and citrate, which in turn inhibits key enzymes in the glycolysis pathway. 
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(Continued from page 11) 
 
III. Problems with the Metabolic Inflexibility Hypothesis and Alternatives 
Despite its widespread acceptance, whether metabolic inflexibility could explain 
tissue-specific insulin resistance in vivo remains to be confirmed. In fact, the 
indirect calorimetric technique employed in Kelley’s original studies have 
significant methodological shortcomings that preclude making definitive 
conclusions about tissue-specific substrate oxidation and changes therein. For 
one, measurements of respiratory quotient using arterio-venous (A-V) respiratory 
quotient (RQ) measurements across the leg were not truly muscle-specific but 
reflect glucose and fat oxidation in additional tissues such as fat and bone. Further, 
indirect calorimetry captures substrate disappearance from blood rather than true 
cellular oxidation and does not account for interconversions between metabolic 
substrates that occur in vivo and thus, is an imperfect measurement for true 
substrate oxidation in the cell (33). To date, no conclusive evidence exists that 
insulin resistant muscles have altered substrate preference in the fasting state and 
that the blunting of insulin’s ability to increase muscle glucose oxidation is a result 
of oxidative inflexibility rather than a primary defect in insulin-mediated glucose 
transport. 
In fact, evidence suggests that the defect in muscle insulin response in T2D 
occurs at the level of insulin response, with impairments in the ability of insulin to 
increase glucose transport across the membrane. A series of in vivo human 
studies utilizing non-invasive magnetic resonance spectroscopy demonstrated that 
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muscles of individuals had impaired glycogen synthesis not as a result of a 
‘backlog’ and allosteric inhibition from disordered downstream oxidation, but from 
a deficiency of substrate secondary to impaired insulin-stimulated GLUT4 
translocation and defective glucose transport across the sarcolemma (34–37). 
Furthermore, significant accumulation of ectopic intramyocellular lipid has been 
observed in the early stages of insulin resistance in individuals susceptible to T2D; 
subsequent experiments  showed that this ectopic lipid deposit increases 
intracellular concentrations of bioactive lipid species such as diacylglycerols 
(DAG), which in turn activates novel protein kinase C (PKC) isoforms that interfere 
significantly with the intracellular insulin signaling transduction, particularly at the 
level of insulin receptor substrate 1 (IRS1) (38–42). Taken together, these studies 
suggest that, contrary to the metabolic inflexibility hypothesis, the primary 
molecular insult in muscle insulin resistance is a proximal impairment in insulin 
response and glucose transport secondary to excessive caloric intake and ectopic 
lipid accumulation, rather than a backlog mechanism from a distal inflexibility in 
mitochondrial substrate handling.  
 
IV. Aims and Hypothesis 
To directly assess the metabolic inflexibility hypothesis and avoid the limitations of 
the A-V indirect calorimetry methodology we applied a novel combined stable 
isotope tracer/LC-MS/MS approach to capture true muscle-specific substrate 
oxidation and examine whether ‘metabolic inflexibility’ is operating in an in vivo 
model of insulin resistance. By infusing [13C6] glucose and analyzing 13C 
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enrichments of alanine and glutamate isotopologues in muscles, we measured 
mitochondrial pyruvate dehydrogenase flux (VPDH) as a proportion of mitochondrial 
citrate synthase flux (VCS), a highly sensitive and tissue-specific index for the 
relative contribution of glucose oxidation to total mitochondrial oxidation 
(VPDH/VCS). Using this method, we studied how induction of insulin resistance in 
rats by high fat feeding affects substrate preference in the fasted state as well as 
during a hyperinsulinemic-euglycemic clamp, which simulates the fed state. In 
addition, we tested whether acute infusion of lipid during a hyperinsulinemic-
euglycemic clamp, thus putting glucose and fatty acids in direct competition, in 
normal rats could acutely modulate substrate oxidation in vivo and whether these 
modulations in muscle oxidative substrate preference correlated with changes in 
whole body insulin sensitivity.  
 We hypothesized that: 
1. The major oxidative substrate during fasting is fat, not glucose. 
2. Oxidative substrate preference in the fasting state in skeletal muscle is not 
different between normal and insulin resistant subjects. 
3. Insulin increases glucose transport, glycolytic flux, and glucose oxidation in 
normal subjects. In insulin resistant subjects, the increase in glucose 
oxidation is blunted. 
4. Failure to increase glucose oxidation in response to insulin in insulin-
resistant subjects is due to impaired insulin-mediated glucose transport, not 
due to metabolic inflexibility or due to defects in cellular oxidative 
machinery.   
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Methods 
I. Experimental Design 
The study design consisted of two rat populations, one fed regular chow and the 
other fed four weeks of a high fat diet (HFD) that induces insulin resistance. 
Surgical placement of arterial and venous catheters enabled infusions of various 
tracers and bioactive agents in live, awake, and non-stressed rats, as well as 
sampling of venous blood for the measurement of real-time concentrations of 
metabolites. This design allowed us to study of dynamic changes in whole-body in 
vivo metabolism rather than relying on in vitro or partial systems. Insulin 
sensitivity/resistance was measured using hyperinsulinemic-euglycemic clamps, 
in which a standardized rate of insulin and variable rates of glucose are infused 
together in the rats to maintain euglycemia (~100 mg/dL) and the rate of glucose 
required provides a quantitative index of the animal’s sensitivity to insulin. To study 
muscle substrate oxidation, normal and HFD-fed rats were given a two-hour trace 
infusion of glucose uniformly labeled with 13C (i.e. all six of its carbons are 13C); 
the infusion of trace amounts ensured that the exogenous infusion of glucose did 
not reflect a substantive increase in total substrate seen by the tissues of interest, 
while the two-hour infusion time enabled the concentrations of tracer and its 
downstream metabolites to reach steady state in blood and tissues. The infusions 
of the glucose tracer were performed both after an overnight fast (which we 
designated as the animal’s basal state), and concomitantly during a 
hyperinsulinemic-euglycemic clamp (which simulated the hyperinsulinemic 
conditions of the fed state). At the conclusion of the infusions, the rats were 
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sacrificed and tissues of interest were quickly harvested and freeze-clamped in 
liquid nitrogen to minimize post-mortem/ischemic changes.  
 In order to measure relative rates of glucose and fat oxidation in skeletal 
muscle, tissue samples were analyzed for enrichments of in downstream 
intracellular metabolites of the labeled glucose. Enrichment is defined as the 
proportion of a labeled isotope to its native, non-labeled form. In the case of our 
study, the infused glucose tracer mixes in blood with endogenous unlabeled 
glucose, and the mixed pool of endogenous and isotopic glucose is taken up by 
the myocyte. In the myocyte, the mixed glucose pool undergoes glycolysis and the 
resulting acetyl-coA participates in the tricarboxylic acid cycle in mitochondria. The 
downstream metabolites produced as a result of these intracellular glycolytic and 
oxidative processes exist in mixed pools of native molecules and isotopes (i.e. 
endogenous glucose will produce unlabeled acetyl-coA with glycolysis, while the 
tracer will produce acetyl-coA with both of its carbons labeled with 13C), and the 
particular enrichments of each downstream metabolite depends on the starting 
enrichment of the upstream substrate, as well as any subsequent dilutions from 
endogenous metabolites contributed by other intracellular pathways. As an 
example, the major processes that contribute to the intracellular acetyl-coA pool 
include glycolysis, beta oxidation of lipids, and breakdown of ketones. While with 
an infusion of glucose tracer glycolysis will increase the pool of labeled acetyl-coA, 
any acetyl coA produced from beta oxidation or ketone oxidation will result in the 
dilution of the enrichment of the intracellular acetyl-coA pool (Graphic 3). Insofar 
as we can measure the enrichments of various metabolites and have a working 
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model of the major cellular reactions contributing to the production, modification, 
and degradation of these metabolites, we can relate the measured enrichments to 
the rate of the reactions affecting them.  
In a previous study, we showed that the using the ratio of measured 
enrichments in select isotopes of alanine and glutamate in the tissues samples of 
rats infused with labeled glucose tracer could be used to approximate the ratio of 
in vivo glycolytic flux to the total oxidative flux (VPDH/VCS), or the relative 
contribution of glucose oxidation to total oxidation in the myocyte (43). 
Theoretically, calculating VPDH/VCS requires measurement of enrichments of 
intracellular pyruvate and acetyl-coA, as the enzyme pyruvate dehydrogenase 
converts pyruvate into acetyl-coA and is the final link between glycolysis and the 
TCA cycle. In reality, intracellular pyruvate is difficult to measure consistently, while 
intracellular acetyl-CoA is prone to rapid postmortem ischemic degradation. 
Therefore, in conditions of steady state with infusion of our tracer, we assumed 
that intracellular pyruvate enrichment equilibrates with the enrichment of alanine 
(a related three-carbon molecule produced by the transfer of an amino group from 
pyruvate), while the acetyl-coA enrichment equilibrates with α-ketoglutarate, which 
in turn equilibrates with the enrichment of the glutamate pool (in particular, 
glutamate enriched at the 4,5 carbon positions, the expected enrichment positions 
of any 13C contributed by the acetyl-coA derived from the infused tracer). Alanine 
and glutamate form stable intracellular pools in steady state that can be measured 
consistently and is relatively resistant to rapid postmortem changes (Graphic 4). 
However, in order to definitively show that alanine and glutamate enrichments 
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would serve as appropriate surrogates for pyruvate and alanine, respectively, we 
performed a series of validation experiments comparing the  
 20 
 
Graphic 4. In tissue samples, the ratio of measured glutamate (m+2) enrichment to alanine (m+3) enrichment 
reflects the ratio of glucose oxidation to total mitochondrial oxidation (VPDH/VCS). A VPDH/VCS ratio of 0 results 
from 100% fat oxidation relative to total oxidation, while a ratio of 1 suggests sole contribution of glucose 
oxidation to total oxidation. 
Graphic 3. A schematic demonstrating the conceptual basis for our tracer approach for determining tissue-
specific substrate oxidation. The infused [13C6] glucose is taken up by the muscle cell, and the labeled carbons 
assume predictable positions in downstream metabolites. The pool of labeled acetyl-coA from the glucose tracer 
is diluted by contributions from beta oxidation of fatty acids, such that measurement of proportional labeling (i.e. 
enrichment) of particular metabolites before and after this dilution can be used to determine relative glucose and 
fat oxidation rates at the cellular level. The schematic also shows our assumption that pyruvate and α-
ketoglutarate enrichments equilibrate with alanine and glutamate enrichments, respectively.  
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enrichments of these pools in a variety of physiologic conditions, including fasting 
and hyperinsulinemic states.  
Using the above approach, we measured tissue-specific substrate oxidation 
(i.e. VPDH/VCS) in skeletal muscle for both fast-twitch and slow-twitch skeletal 
muscle. We studied how substrate oxidation changes compares between normal 
and HFD-fed insulin resistant rats, during both fasting and fed-simulated (i.e. 
hyperinsulinemic) conditions. To further test the validity of the metabolic inflexibility 
hypothesis and to see whether there was metabolic ‘overload’ occurring in the 
mitochondria in insulin resistant muscle, we measured levels of key oxidative 
enzymes (pyruvate dehydrogenase, pyruvate dehydrogenase kinase, carnitine 
palmitoyl transferase, and carnitine o-acetyl transferase) in tissues of both normal 
and HFD-fed rats. To study the changes in insulin signaling with insulin resistance, 
we measured levels and activities (as indicated by the proportion of 
phosphorylated to total levels) of key enzymes in the insulin signaling cascade, as 
well as concentrations of lipid species previously shown to interfere with insulin 
signaling.  
 To study the effect of acute modulation of muscle substrate oxidation and 
its relation to insulin resistance, we studied another cohort of normal rats and 
compared them under two conditions, one during a hyperinsulinemic-euglycemic 
clamp, the other during a co-infusion of non-esterified fatty acid during a 
hyperinsulinemic-euglycemic clamp. Insulin is a powerful suppressor of 
endogenous lipolysis; thus, the control group saw almost no fatty acid, while co-
infusion of fatty acid during the clamp raised the level of plasma fatty acid to fasting 
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levels and provide and increase fatty acid oxidation in skeletal muscle. As 
previously with our comparison of normal and HFD-fed rats, we performed 
infusions of uniformly-labeled glucose tracer, measured VPDH/VCS in skeletal 
muscle samples, measured levels of key oxidative enzymes as well as 
mitochondrial metabolites, and measured the phosphorylation of key enzymes in 
the insulin signaling cascade. 
 Further information about the particular materials and specific protocols 
used to undertake components of the above-mentioned overarching experimental 
design are listed in detail below. Included at the conclusion of the methods section 
is a statement about which components of the experiment were performed by the 
author and which were performed by collaborating scientists.  
 
II. Experimental Model And Subject Details 
All animal studies were approved by the Yale University Institutional Animal Care 
and Use Committee and were performed in accordance with all regulatory 
standards. 250 g male Sprague-Dawley rats were obtained from Charles River 
Laboratories (Wilmington, MA) and were group housed (3 per cage) while they 
were fed either a high fat diet (Dyets #112245, Bethlehem, PA; 59% calories from 
fat, 26% from carbohydrate, 15% from protein) or a chow diet (Harlan Teklad 
#2018, Madison, WI; 18% calories from fat, 58% from carbohydrate, 24% from 
protein), ad lib for 3 weeks. All rats then underwent surgery under general 
isoflurane anesthesia for placement of polyethylene catheters in the common 
carotid artery (PE50 tubing, Instech Solomon, Plymouth Meeting, PA) and the 
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jugular vein (PE90 tubing, Instech), after which they were singly housed. The rats 
were fed their respective diets ad lib for 1 more week, after which they were studied 
and sacrificed. All in vivo studies were performed following an overnight (16 hr) 
fast. At the conclusion of each study, rats were euthanized by IV pentobarbital. 
 
III. Method Details 
Animal Studies 
In all studies, tracers were infused through a catheter placed ∼1 week prior in the 
carotid artery, and blood was obtained from a catheter in the jugular vein. Unless 
otherwise specified, all blood was drawn from the jugular vein. All studies began 1 
hr after catheters were connected, reducing any impact of stress from handling on 
the physiology assessed. 
 
Flux Analysis 
To measure VPDH/VCS flux in the basal fasted state, rats were infused with 
[1,2,3,4,5,6-13C6]glucose (prime 3 mg/[kg-min] for 5 min, continuous infusion rate 
1 mg/[kg-min]) for a total of 120 min, after which blood (600 µl whole blood) was 
obtained from the venous catheter and immediately centrifuged and the plasma 
obtained, and rats were sacrificed and their soleus and quadriceps muscles snap-
frozen in situ using metal tongs pre-chilled in liquid N2. The VPDH/VCS flux was 
measured as the ratio of [4,5-13C2]glutamate / [13C3]alanine in soleus and 
quadriceps after a 2 hr infusion of [1,2,3,4,5,6-13C6]glucose (16.7 μmol/[kg-min] 
prime for 5 min, 5.6 μmol/[kg-min] continuous infusion) based on the assumptions 
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we have described previously (43–45). Alanine enrichment was measured by 
GC/MS: samples were deprotonized with 5 volumes of methanol and derivatized 
with 3 volumes of b-butanol 4N HCl, after which the samples were heated to 65°C 
for 60 min, evaporated under N2 gas, and resuspended in 100 μL of trifluoroacetic 
acid:methylene chloride (1:7). GC-MS was then used to determine the m+4 alanine 
enrichment (retention time ∼4.1 min, m/z 242 [m0], 243 [m+1], 244 [m+2], 245 
[m+3], 246 [m+4]). Glutamate enrichment was measured by LC-MS/MS: the 
samples were homogenized in 500 μL ice-cold methanol using a TissueLyser and 
filtered through a Nanosep filter. LC-MS/MS (AbSCIEX 6500 QTRAP with a 
Shimadzu ultrafast liquid chromatography system, negative ion mode) was used 
to monitor the relevant ion pairs: [m0] C4-5 glutamate, 146/41, [m+1] C4-5 
glutamate, 147/47, and [m+2] C4-5 glutamate, 148/48. 
To measure muscle glucose uptake, a bolus of [6,6-14C]2-deoxyglucose 
was administered in all rats. The harvested soleus and quadriceps muscles were 
processed to determine glucose uptake in both tissues by comparing the plasma 
[14C] specific activity decay curve to tissue [14C] specific activity, both measured 
using a scintillation counter (46). 
 
Hyperinsulinemic Glucose Clamps 
Rats were given a 40 mU/kg bolus of Regular insulin followed by a 2 hr insulin 
infusion at a rate of 4.0 mU/(kg-min), while euglycemia was maintained with 
variable infusion of [1,2,3,4,5,6-13C6]glucose. Blood samples were drawn from the 
venous catheter at 0, 15, 30, 45, 60, 70, 80, 90, 100, 120 min of the clamp, with 
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the samples from the 120 min time point used to measure clamp glucose turnover. 
Plasma insulin was measured by radioimmunoassay by the Yale Diabetes 
Research Center at the 0 and 120min time points of the clamp. Glucose turnover 
in the clamp was calculated as above 𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 = *+,-./,	/1,2.34/15
67-84-	/1,2.34/15
− 1; ∗
𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛	𝑟𝑎𝑡𝑒, and the rate of whole-body glucose disposal was calculated as the 
sum of the glucose infusion rate plus the glucose turnover rate measured in the 
clamp. 
 
For combined lipid infusion and hyperinsulinemic-euglycemic clamps, rats were 
infused with Intralipid 20% emulsion (Baxter Inc.) at the rate 40 µL/[kg-min] in 
addition to variable infusions of [1,2,3,4,5,6-13C6]glucose tracer for 2 hours. Plasma 
samples from 0 and 120 min time points for 2 hr lipid infusions were used to 
measure plasma non-esterified fatty acid levels with the method described below. 
 
Biochemical Analysis 
Plasma glucose concentrations were measured enzymatically using the YSI 
Glucose Analyzer (Yellow Springs, OH). Plasma NEFA concentrations were 
measured spectrophotometrically using a Wako reagent (Wako Diagnostics, 
Mountain View, CA). 
 
Tissue Analysis 
Muscle DAG and ceramide concentrations (40), acetyl- and malonyl-CoA (47,48) 
were measured as we have described. Muscle PKCq membrane/cytosol ratio (49), 
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insulin receptor phosphorylation relative to total insulin receptor, and Akt 
phosphorylation relative to total Akt were measured by Western blot using 
antibodies from Cell Signaling. PDH phosphorylation  relative to total PDH was 
measured by Western blot using antibodies from Calbiochem (pPDH s300, s232, 
s293) and Abcam (PDH). Glucose-6-phosphate concentrations were measured 
using an enzymatic assay from Sigma-Aldrich. Pyruvate concentrations were 
measured using GC/MS after derivatization with o-phenylene-diamine (Sigma-
Aldrich) dissolved in 4M HCl, extraction with ethyl acetate, and further 
derivatization of the dried organic layer with a 1:1 BSTFA (Sigma-Aldrich) and 
pyridine (Sigma-Aldrich) mixture. Concentrations of TCA cycle intermediates 
(citrate, malate, succinate) were measured as reported previously (45). IRS-1-
associated PI3-kinase activity was measured as reported previously (40). CPT1b 
was measured using antibodies from Santa Cruz. CrAT was measured using 
antibodies from ProteinTech. PDH, CPT1b, and CrAT levels were normalized to 
GAPDH levels, which was measured with antibodies from Cell Signaling. Muscle 
concentrations of G-6-P, pyruvate, acetyl-CoA, malonyl-CoA, and TCA cycle 
intermediates were measured in tissues freeze-clamped in situ to minimize 
changes due to post-mortem ischemia. 
 
IV. Quantification And Statistical Analysis  
Comparisons were performed using the 2-tailed Student’s t-test, unpaired unless 
otherwise specified in the figure legends, with significance defined as a p-value 
<0.05. GraphPad Prism 7.0 (San Diego, CA) was used for all statistical analysis. 
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In most cases, n=8-10 rats per group, unless otherwise indicated in the figure 





All animal experiments were designed/conducted and all data were analyzed 
independently by the author during the 2017-2018 academic year, with financial 
support from the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), under the guidance of Dr. Gerald I. Shulman, Dr. Gary Cline, and Dr. Kitt 
F. Petersen. Preliminary experiments demonstrating the feasibility of using 
uniformly-labeled glucose tracer for the study of tissue-specific VPDH/VCS were 
performed by Tiago Alves, a former graduate student in the Shulman lab. The 
author learned how to perform clamps and tracer infusion experiments under the 
tutelage of Rachel Perry, a former postdoctoral fellow in the Shuman lab. Rachel 
Perry and graduate students Alexander Munk and Ye Zhang provided technical 
assistance during clamp and infusion experiments.  
The following contributions were from staff scientists in the Shulman lab. 
Gina Butrico and Xian-Man Zhang provided assistance with the use of mass 
spectrometry (both liquid and gas chromatography) for the measurement of 
intracellular metabolite concentrations and their enrichments. Mario Kahn provided 
assistance with measurement of intramyocellular lipid species. Dongyan Zhang 
 28 
instructed the author on western blot technique and assisted with the PI3K assay. 





In comparison to normal chow fed rats, rats fed 4 weeks of a high fat diet (HFD) 
exhibited increased body weight (Fig. S1A) and became insulin resistant, as 
manifested by higher plasma insulin levels required to maintain the same level of 
plasma glucose in the fasting state (Fig. S1B, D) as well as by reduced glucose 
infusion rate required to maintain euglycemia during a hyperinsulinemic-
euglycemic clamp (Fig. S1G). Furthermore, insulin-stimulated muscle glucose 
uptake (Rd) and muscle glucose transport, as measured by radioactive 2-
deoxyglucose uptake, were significantly impaired during the clamp (Fig. 1A-B), 
confirming the presence of skeletal muscle insulin resistance in these rats. 
 To test whether the metabolic inflexibility hypothesis could explain the 
development of muscle insulin resistance in these HFD-fed rats, we sought to 
study whether the HFD-fed rats had altered oxidative substrate preference in 
skeletal muscle in the basal state. We used [13C6] glucose as a tracer during the 
clamp and used tissue-specific enrichments of alanine and glutamate to measure 
in vivo VPDH/VCS in soleus and quadriceps muscles (43). As mentioned in the 
methods section, although calculation of true VPDH/VCS requires the comparison of 
intracellular pyruvate and acetyl CoA enriched by the [13C6] glucose tracer, these 
metabolites undergo rapid ex vivo degradation and are difficult to measure. Under 
conditions of steady state, intracellular pyruvate [m+3] was assumed to equilibrate 
with alanine [m+3], and acetyl CoA [m+2] was assumed to equilibrate with C4C5 
glutamate [m+2]. Both alanine and glutamate are more stable ex vivo relative to 
their respective counterparts and were more amenable to reliable and consistent 
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measurement of their intracellular enrichments. A rigorous comparison study of the 
enrichments of these metabolites (performed in rat tissues freeze-clamped in situ 
to minimize ischemic degradation) showed significant and near 1:1 correlations 
between alanine and pyruvate enrichments as well as between C4C5 glutamate 
and acetyl CoA enrichments under a variety of experimental conditions (Fig. S3A-
B), validating our equilibration assumptions and indicating that alanine and C4C5 
glutamate enrichments could be reliably used to approximate in vivo VPDH/VCS.  
Using this approach, we found that, contrary to what Kelley et al. had 
observed in humans using, A-V indirect calorimetry, skeletal muscles of normal 
rats relied predominantly (>90%) on fat oxidation in the fasting state (Fig. 1C-F) 
(27,50). Furthermore, in contrast to what the metabolic flexibility hypothesis would 
predict, we found that this overwhelming preference for fat oxidation in both soleus 
and quad muscle during the fasting state did not change in insulin resistant HFD-
rats (Fig. 1C-F). In response to insulin during a clamp, normal rats upregulated 
relative glucose oxidation in soleus muscle to ~50% and in quad muscles, which 
contain a lower proportion of slow twitch (oxidative) to fast twitch (glycolytic) fibers, 
to ~25% (Fig. 1C-F). In HFD-fed rats, however, this increase in glucose oxidation 
in response to insulin was blunted in both skeletal muscles (Fig. 1C-F). These 
results indicated that insulin resistance in the HFD-fed rats was characterized not 
by alterations in basal substrate use but by a defect in their ability to increase 
glucose oxidation in the presence of insulin. 
 This impairment in the ability of HFD-fed rats to increase glucose oxidation 
with insulin could have resulted either from a defect in the mitochondrial oxidative 
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capacity or from limited substrate availability secondary to a defect in insulin-
mediated glucose transport. To see which was operating in our rat model of insulin 
resistance, we measured basal levels of key oxidative enzymes and found that 
there were no differences in the expression of PDH, CPT1b (the isoform of CPT 
predominant in skeletal muscle), and CrAT, a regulator of the mitochondrial acetyl-
CoA pool that was suggested as a candidate for altered substrate handling in the 
metabolic inflexibility hypothesis of insulin resistance (Fig. 2C). Furthermore, we 
found no difference in the phosphorylation of PDH in both fasting and clamped 
states between the two groups, suggesting that HFD-fed rats did not have impaired 
activity of PDH and capacity to oxidize glucose (Fig. 2A). Finally, muscle 
concentrations of tricarboxylic acid cycle metabolites were not altered with HFD 
(Fig. 2B), making it unlikely that the mitochondria of insulin resistant rats had 
‘metabolic overload’ that might impede smooth transitions between fat and glucose 
oxidation. All in all, we did not find evidence that the mitochondria of HFD-fed rats 
acquired defects in mitochondrial oxidative capacity that could explain the 
impairments in insulin-stimulated glucose oxidation we observed in skeletal 
muscle. To test whether impairments in glucose transport could provide an 
alternative explanation, we measured previously reported mediators of ectopic 
lipid-induced blockage of insulin signaling and found that HFD-fed rats displayed 
increased baseline translocation of protein kinase Cq (PKCq) and impaired 
phosphorylation of AKT in response to insulin (Fig. 2D,F). Furthermore, HFD-fed 
rats showed significantly reduced insulin receptor substrate-1 (IRS-1)-associated 
phosphoinositide 3-kinase (PI3-K) activity, a proximate and sensitive indicator of 
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insulin-stimulated glucose transport (Fig. 2E). Altogether, these results support the 
hypothesis that the major defect in the early stages of the pathogenesis of muscle 
insulin resistance is ectopic lipid-induced blockage in insulin-mediated glucose 
transport due to proximal defects in insulin signaling, rather than acquired 
‘metabolic inflexibility.’ 
 Given that insulin resistant rats fed HFD failed to display alterations in basal 
substrate use, we wanted to see if acute modulation of intramyocellular substrate 
oxidation in normal rats could influence muscle insulin response. 
Hyperinsulinemic-euglycemic clamps suppressed fasting white adipocyte tissue 
(WAT) lipolysis as exhibited by reductions in non-esterified fatty acid (NEFA) from 
~1.0 mM to ~0.2 mM, but concomitant infusion of intralipid during a clamp raised 
NEFA back to approximately fasting plasma concentrations (~1.2 mM) (Fig. S2F). 
Providing NEFA in competition with glucose led to significant reductions (~50%) in 
relative glucose oxidation in both soleus and quadriceps as measured by VPDH/VCS 
(Fig. 3C-D), which occurred independently of changes in phosphorylation of PDH 
(Fig. S2H). Interestingly, infusion of intralipid increased intramyocellular acetyl-
CoA and glutamate concentrations but not glucose-6-phosphate or citrate 
concentrations (Fig. 3F). This constellation of changes in intracellular metabolites 
with increased fat oxidation is consistent with acetyl-CoA-mediated allosteric 
inhibition of PDH activity, but not with Randle’s proposed mechanism of fat 
oxidation-induced inhibition of key glycolytic steps and glucose uptake, which 
predicts increases in glucose-6-phosphate and citrate concentrations with 
increased fat oxidation (25,51). Furthermore, we found that the significant 
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reduction in muscle glucose oxidation seen in the intralipid group was not 
accompanied by any changes in measures of in vivo muscle insulin response such 
as whole-body glucose uptake, muscle glucose transport, and muscle AKT 
phosphorylation (Fig. 3A-B, E), dissociating alterations in substrate oxidation from 





























































































































































































































































































































































































































































































































































































































































































































































































































































y = 1.023x + 0.997
P < 0.0001
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The precise mechanism leading to the development of muscle insulin resistance 
has not yet been defined, but alterations in mitochondrial substrate preference has 
emerged as an attractive possibility. Randle was the first to hypothesize a path by 
which altered muscle substrate use, namely, increased muscle mitochondrial fatty 
acid oxidation, could inhibit not only glucose oxidation but glucose uptake in 
response to insulin (25,51). More recently as an expansion or update of Randle’s 
proposals, others have suggested that muscle insulin resistance is a result of 
‘metabolic inflexibility,’ or muscle mitochondrial dysfunction that results in 
impairments in its ability to make smooth transitions between utilizing glucose or 
fatty acids as substrates depending on varying physiological needs. These 
hypotheses have located mitochondrial fuel preference as the nexus of muscle 
insulin resistance, in contrast to competing hypotheses that centered on defects in 
insulin signaling and insulin-mediated glucose transport. ‘Metabolic inflexibility’ 
necessarily entails two predictions about insulin resistant muscle: first, that fasting 
or basal substrate preference is altered in insulin resistant muscle due to 
mitochondrial dysfunction; and second, that insulin resistant muscle cannot 
increase glucose oxidation beyond its basal rate as a result of this mitochondrial 
dysfunction (26,27). In this hypothesis, the accumulation of intramyocellular lipid 
observed in insulin resistant muscle is hypothesized to be secondary to an 
impaired mitochondrial ability to oxidize fat, in opposition to other hypotheses that 
have proposed that the buildup of certain lipid metabolites (diacylglycerols, 
ceramides, etc.) lead to inhibition of insulin signaling. 
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 While ‘metabolic inflexibility’ has become a widespread concept, the original 
studies by Kelley had significant methodological shortcomings that leave the 
precise relationship between muscle substrate oxidation and muscle insulin 
response hitherto unresolved (26,27) Furthermore, subsequent studies by other 
groups to identify possible candidate defects for muscle ‘metabolic inflexibility’ 
have predominantly relied on in vitro models or genetic manipulations to show 
altered mitochondrial substrate preference and oxidation. In this study, we used 
HFD-fed rats who were at the early stages of muscle insulin resistance to 
characterize early myocellular changes that mechanistically contributed to the 
development of this phenomenon. Importantly, by infusing a stable isotope tracer 
([13C6]glucose) and analyzing enrichments in particular isotopologues of 
intramyocellular metabolites by LC-MS/MS, we were able to obtain a sensitive 
measure for muscle-specific glucose oxidation relative to total mitochondrial 
oxidation and relate this measure to in vivo indices of muscle insulin resistance in 
normal and HFD-fed rats as well as insulin sensitive and insulin resistant humans. 
With these methods, we sought to adjudicate between two competing hypotheses 
for the pathogenesis of muscle insulin resistance: one in which mitochondrial 
derangements lead to altered substrate preference and prevent insulin-mediated 
glucose uptake by a backlog mechanism; and two in which excess ectopic lipid 
build-up leads to interference with insulin signaling and prevents insulin-mediated 
glucose transport.  
 Our results contradict the predictions of the ‘metabolic inflexibility’ 
hypothesis in three major ways. First, while Kelley et al. had observed relative 
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glucose oxidation in normal fasting muscle contributed a significant proportion of 
total oxidation at 40% (27), we found relative glucose oxidation normal fasting 
muscle to be minimal at less than 10% in both soleus (primarily type I oxidative 
fibers) and quadriceps (primarily type II glycolytic fibers) (52). Second, while the 
‘metabolic inflexibility’ hypothesis predicts that fasting substrate use in insulin 
resistant muscle would be significantly altered in favor of increased glucose 
oxidation, we found that the fasting muscles of insulin resistant rats did not differ 
from muscles of normal rats in their substrate preference and also relied 
overwhelmingly on fat oxidation (Fig. 1C-F). This lack of altered fasting substrate 
preference was corroborated by the absence of significant changes in muscle 
mitochondrial oxidative function and capacity in insulin resistant rats, as indicated 
by unchanged expressions of key mitochondrial oxidative enzymes such as PDH, 
CPT1b, and CrAT (Fig. 2C), and by unchanged concentrations of mitochondrial 
TCA cycle metabolites (Fig. 2B). Finally, whereas Kelley et al. had observed that 
insulin resistant muscle could not upregulate relative glucose oxidation in response 
to insulin (i.e. were metabolically inflexible), we found that muscles of insulin 
resistant rats increased relative glucose oxidation with insulin (i.e. were 
metabolically flexible), though the increase was blunted compared to normal 
muscle (Fig. 1C-F).  This blunting of increased glucose oxidation was likely 
secondary to defects in insulin signaling (Fig. 2E) and insulin-mediated glucose 
transport (Fig. 2B, D, F) in insulin resistant rats. Taken together these data 
demonstrate that the muscles of insulin resistant rats were in fact metabolically 
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flexible but that this metabolic flexibility was constrained by defects in insulin-
mediated glucose transport.  
If muscle insulin resistance is not characterized by alterations in muscle 
substrate use, we asked conversely whether modulations in muscle substrate use 
in normal rats could affect insulin sensitivity. We found that changes in muscle 
substrate oxidation were dissociated from muscle insulin response. Infusion of 
intralipid in normal rats during a hyperinsulinemic-euglycemic clamp raised plasma 
fatty acid levels and significantly reduced glucose oxidation in muscle, but did not 
alter muscle glucose uptake, muscle glucose transport, or muscle insulin signaling 
(Fig. 3A-E). Furthermore, we did not find evidence for Randle’s proposed glucose-
fatty acid cycle in which increased fatty acid oxidation in the myocyte could inhibit 
glucose oxidation and glucose uptake through inhibition of key regulated steps in 
glycolysis. While Randle had observed in in vitro studies that increased fat 
oxidation led to increased levels of acetyl CoA, citrate, and glucose-6-phosphate, 
we found that only acetyl CoA concentrations were increased in vivo (Fig. 3F), 
suggesting that fatty acid oxidation could inhibit glucose oxidation through 
allosteric inhibition of PDH (and not through inhibition of key glycolytic steps) but 
that this reduced PDH flux was ultimately inconsequential in the larger picture of 
muscle insulin response. Together with a recent study which found the 
complementary result that acutely increasing PDH flux with dichloroacetate did not 
affect muscle insulin sensitivity (53), these data dissociate changes in substrate 
oxidation from muscle insulin sensitivity and suggest that attempts to develop 
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therapeutics to treat insulin resistance and type 2 diabetes by targeting 
mitochondrial substrate preference would likely prove ineffective.  
Though we do not find evidence of ‘metabolic inflexibility’ in the 
pathogenesis of muscle insulin resistance nor of any mechanistic relationship 
between modulation of mitochondrial substrate preference and muscle insulin 
sensitivity, these data should not be taken as evidence that mitochondrial 
dysfunction more broadly is insignificant to the development of metabolic disease. 
In fact, robust evidence exists that reductions in mitochondrial function may be an 
important predisposing contributor to myocellular lipid accumulation and muscle 
insulin resistance in the lean offspring of parent with type 2 diabetics (54–56) and 
the elderly (57). These effects, however, could be attributed to reductions in total 
mitochondrial energy expenditure leading to increased ectopic lipid accumulation 
and not to specific alterations in substrate utilization. Consistent with overall 
reductions in skeletal muscle mitochondrial function as previously documented by 
both in vivo 31P magnetic resonance spectroscopy (MRS) (56) and 13C MRS (54) 
we also observed a reduction in insulin-stimulated muscle mitochondrial VCS flux 
in the insulin resistant subjects as assess by in vivo 13C MRS. Thus, it is important 
to distinguish mitochondrial substrate preference per se, which these data 
demonstrate has little impact on the development of muscle insulin resistance, 
from reductions in overall mitochondrial function and fat oxidation that leads to the 
imbalance of energy intake and expenditure, ectopic lipid build-up, and insulin 
resistance. In support of this hypothesis Knowles et al. have recently identified a 
gene variant in N-acetyl transferase-2 (Nat2) in humans that is associated with 
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T2DM (58). Nat1 (mouse homologue) knockout mice display reduced whole-body 
energy metabolism (58,59), reduced mitochondrial function, increased ectopic lipid 
deposition and liver and muscle insulin resistance (59).    
In summary, these studies demonstrate that in contrast to the tenets of the 
metabolic flexibility hypothesis there are no alterations in basal rates of 
mitochondrial VPDH/VCS flux in insulin resistant human or rodent skeletal muscle 
thus providing strong evidence against hypotheses that relate alterations in muscle 
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